Co-led by
A total of 85 patients with non-small cell lung cancer (NSCLC) who received immune checkpoint inhibitors (ICI) were analyzed for the study. According to the study, the utilization of Lunit SCOPE IO for TLS evaluation yielded clinically significant correlations with patients' overall survival (OS). 25 patients with detected TLS had notably prolonged overall survival compared to 60 patients without TLS. This correlation remained consistent irrespective of PD-L1 expression, a known biomarker for treatment response in NSCLC patients.
These findings underscore the potential of AI-based TLS analysis as a biomarker for predicting treatment response in NSCLC patients.
'Through rigorous collaboration and cutting-edge technology, our study illuminates a promising path toward better predicting lung cancer treatment outcomes. The potential of TLS analysis via Lunit SCOPE IO in predicting immunotherapy response represents a meaningful step forward in better understanding cancer biology, and making AI analysis of the TME an actionable part of cancer care,' said
Lunit SCOPE IO was developed with a dataset of thousands of Hematoxylin and Eosin (H&E) stained whole-slide images derived from 18 different types of cancer from patients around the world.
Contact:
Email: contact@lunit.io
(C) 2023 Electronic News Publishing, source